Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium (ICDS), June 24, 2015, in Prague, Czech Republic.
The abstract, entitled, "Rationale for AMG 714, an anti-IL-15 mAb, in the treatment of celiac and refractory celiac disease," is scheduled to be presented during the Novel Treatment session, on Wednesday, June 24, 2015, from 11:00am – 12:30pm CEST.
AMG 714 is a Phase 2, anti-IL-15 monoclonal antibody that Celimmune has licensed from Amgen (NASDAQ: AMGN) and is developing for the treatment of diet non-responsive celiac disease and Type II refractory celiac disease (RCD II), an in situ small bowel T cell lymphoma. IL-15 is a molecule produced by the immune system and intestinal cells that is considered to be a central regulator of celiac disease and a driver of lymphoma growth in RCD II. IL-15 has been shown to be one of the key factors in the loss of tolerance to food antigens, and it also is believed to be involved in Crohn's disease and other autoimmune and inflammatory diseases.
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR